在患有非小细胞肺癌(NSCLC)的患者中,免疫检查点抑制剂(ICIs)的疗效尚不确定.我们的研究旨在检查携带KRAS的NSCLC患者的一线ICI疗效,MET,FGFR,RET,BRAF,和HER2在现实世界中的改变。
这个单中心,回顾性队列研究包括携带KRAS的晚期非小细胞肺癌患者,MET,FGFR,RET,BRAF,HER2改变或驾驶员阴性,并接受一线ICI治疗。最好的整体反应,无进展生存期(PFS),评估总生存期(OS)。
纳入78例NSCLC患者(中位年龄,72岁):67%是男性,15%的人从不吸烟。83%患有腺癌。驾驶员变更涉及KRAS(n=21),MET(n=6),FGFR(n=3),RET(n=2),BRAF(n=2),HER2(n=1),和驱动负(n=43)。KRAS的部分反应,MET,FGFR,RET,BRAF,HER2和驾驶员阴性为57%,50%,100%,50%,100%,0%,47%,分别。KRAS的中位PFS(月)为16.2(95%置信区间[CI]:6.3-未达到[NR]),MET为2.8(95%CI:2.7-NR),11.7(95%CI:5.9-NR)用于其他改变(FGFR,RET,BRAF,和HER2),驾驶员阴性为10.0(95%CI:3.7-14.3),分别。KRAS的中位OS(月)为31.3(95%CI:9.0-NR),没有到达MET,其他变更为23.5(95%CI:18.3-NR),和21.1(95%CI:15.2-NR)为驾驶员阴性,分别。
在晚期非小细胞肺癌中,一线ICI的益处是相似的,无论驱动因素如何改变,除了MET改变。
In patients with non-small cell lung cancer (NSCLC) harboring driver alterations, the efficacy of immune checkpoint inhibitors (ICIs) remains uncertain. Our study aimed to examine the first-line ICI efficacy in patients with NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 alterations in a real-world setting.
This single-center, retrospective cohort study included patients with advanced NSCLC harboring KRAS, MET, FGFR, RET, BRAF, HER2 alterations or driver-negative, and were treated with first-line ICI therapy. Best overall response, progression-free survival (PFS), and overall survival (OS) were evaluated.
Seventy-eight patients with NSCLC were included (median age, 72 years): 67% were men, 15% were never-smokers, and 83% had adenocarcinoma. The driver alterations involved KRAS (n = 21), MET (n = 6), FGFR (n = 3), RET (n = 2), BRAF (n = 2), HER2 (n = 1), and driver-negative (n = 43). The partial responses for KRAS, MET, FGFR, RET, BRAF, HER2, and driver-negative were 57%, 50%, 100%, 50%, 100%, 0%, and 47%, respectively. The median PFS (months) was 16.2 (95% confidence interval [CI]: 6.3- not reached [NR]) for KRAS, 2.8 (95% CI: 2.7-NR) for MET, 11.7 (95% CI: 5.9-NR) for other alterations (FGFR, RET, BRAF, and HER2), and 10.0 (95% CI: 3.7-14.3) for driver-negative, respectively. The median OS (months) was 31.3 (95% CI: 9.0-NR) for KRAS, not reached for MET, 23.5 (95% CI: 18.3-NR) for other alterations, and 21.1 (95% CI: 15.2-NR) for driver-negative, respectively.
The benefit of the first-line ICI was similar in advanced NSCLC regardless of the driver alterations, except for MET alterations.